News | Prostate Cancer | June 01, 2016

Clinical Trial Will Test MRI for Improved Prostate Cancer Diagnosis

Researchers hope MRI can provide more targeted alternative to ultrasound-guided biopsy with fewer side effects

prostate cancer, MRI, diagnosis, PRECISE trial, Canada

June 1, 2016 — A new Phase III clinical trial will look to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer. The primary objective of the multi-center PRECISE trial — sponsored by the Movember Foundation, the Ontario Institute for Cancer Research (OICR) and Prostate Cancer Canada — is to determine whether MRI can spare some men from undergoing a biopsy and avoid the possible associated side effects.

The trial will initially receive $3 million in funding. It will be led by Laurence Klotz, M.D., of the Sunnybrook Research Institute in Toronto.

MRI technology is a precise tool that could better identify which patients should undergo biopsy, and enable targeted biopsy of only areas suspected of malignancy. The PRECISE trial, which is estimated to be completed in three years, will investigate the ability of MRI to improve the diagnosis of clinically important disease and reduce the requirement for prostate biopsies.

Currently, prostate cancer is diagnosed by trans-rectal ultrasound (TRUS)-guided biopsy of the prostate, in most cases following a prostate specific antigen (PSA) test. TRUS-guided biopsy is associated with potential side effects such as infection and bleeding because it is not targeted, requiring numerous biopsy samples (between 10 and 12) to establish an accurate reading. In addition, this current standard of care is not sensitive enough to be able to discriminate between high-risk and very low-risk changes in prostate tissue, resulting in the over-diagnosis and over-treatment of many men, exacerbating the risk for side effects.

“If positive, this trial would support a change in practice from relying on biopsies for all men with suspected prostate cancer to providing MRI first with selective targeted biopsy,” explained Klotz. “This would allow 250,000 men per year in the U.S. and Canada to avoid unnecessary biopsies and the associated complications including hospitalization, without compromising our ability to identify clinically significant cancers.”

Data management and analysis for the trial will be conducted by the Ontario Clinical Oncology Group (OCOG) in the Escarpment Cancer Research Institute, a Hamilton Health Sciences and McMaster University institute.

For more information: www.prostatecancer.ca, www.oicr.on.ca

Related Content

Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy
News | Women's Health | August 20, 2019
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent...
New MRI Technique Captures Brain Changes in Near-real Time

Differences in stiffness between stimulus states. Image courtesy of Patz et al.

News | Neuro Imaging | August 19, 2019
An international team of researchers developed a new magnetic resonance imaging (MRI) technique that can capture an...
ADHD Medication May Affect Brain Development in Children

Images of regions of interest (colored lines) in the white matter skeleton representation. Data from left and right anterior thalamic radiation (ATR) were averaged. Image courtesy of C. Bouziane et al.

News | Neuro Imaging | August 16, 2019
A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s...
Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro
Technology | Interventional Radiology | August 16, 2019
Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to...
First Patient Enrolled in World's Largest Brain Cancer Clinical Trial
News | Radiation Therapy | August 15, 2019
Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive...
Efficacy of Isoray's Cesium Blu Showcased in Recent Studies
News | Brachytherapy Systems | August 14, 2019
August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica
Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging

Image courtesy of Imago Systems

News | Mammography | August 14, 2019
Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year...
Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses
News | Artificial Intelligence | August 13, 2019
University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that...